Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryuzo Ohno

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
International Journal of Hematology|May 20, 2011
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysisYukio Kobayashi, Hisashi Sakamaki, Shin Fujisawa, et al.
Leukemia Research|September 29, 2006
Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival ratesMasamitsu Yanada, Itsuro Jinnai, Jin Takeuchi, et al.
European Journal of Haematology|January 24, 2007
Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcomeMasamitsu Yanada, Tadashi Matsushita, Norio Asou, et al.
International Journal of Hematology|January 8, 2011
Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study GroupMinoru Yoshida, Nobu Akiyama, Hiroyuki Fujita, et al.
International Journal of Hematology|May 29, 2012
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 StudyAtsushi Wakita, Shigeki Ohtake, Satoru Takada, et al.
Haematologica|January 29, 2008
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapyMasamitsu Yanada, Jin Takeuchi, Isamu Sugiura, et al.
Leukemia Research|January 18, 2011
BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assayTakaaki Ono, Shuichi Miyawaki, Fumihiko Kimura, et al.
Blood|November 8, 2003
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemiaKazutaka Ozeki, Hitoshi Kiyoi, Yuka Hirose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study GroupMasamitsu Yanada, Jin Takeuchi, Isamu Sugiura, et al.
International Journal of Hematology|February 25, 2022
A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemiaHiroatsu Iida, Kazunori Imada, Yasunori Ueda, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
International Journal of Hematology|May 20, 2011
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysisYukio Kobayashi, Hisashi Sakamaki, Shin Fujisawa, et al.
Leukemia Research|September 29, 2006
Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival ratesMasamitsu Yanada, Itsuro Jinnai, Jin Takeuchi, et al.
European Journal of Haematology|January 24, 2007
Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcomeMasamitsu Yanada, Tadashi Matsushita, Norio Asou, et al.
International Journal of Hematology|January 8, 2011
Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study GroupMinoru Yoshida, Nobu Akiyama, Hiroyuki Fujita, et al.
International Journal of Hematology|May 29, 2012
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 StudyAtsushi Wakita, Shigeki Ohtake, Satoru Takada, et al.
Haematologica|January 29, 2008
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapyMasamitsu Yanada, Jin Takeuchi, Isamu Sugiura, et al.
Leukemia Research|January 18, 2011
BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assayTakaaki Ono, Shuichi Miyawaki, Fumihiko Kimura, et al.
Blood|November 8, 2003
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemiaKazutaka Ozeki, Hitoshi Kiyoi, Yuka Hirose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study GroupMasamitsu Yanada, Jin Takeuchi, Isamu Sugiura, et al.
International Journal of Hematology|February 25, 2022
A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemiaHiroatsu Iida, Kazunori Imada, Yasunori Ueda, et al.
Pageof 8